CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection-and Maybe More.
Despite overwhelming basic science linking inflammation to the pathobiology of atherothrombosis, the specific clinical evidence indicating cardiovascular benefits from anti-inflammatory pharmacotherapy has been lacking. The CANTOS trial (Ridker et al., 2017a) now provides the first largescale proof of concept that inflammasome targeting can reduce cardiovascular events-and, surprisingly, lung cancer.